Presence of human polyomavirus 6 in mutation-Specific braf inhibitor-Induced epithelial proliferations

JAMA Dermatology

Volumn 150, Issue 11, 2014, Pages 1180-1186

  Schrama, David ^a,b   Groesser, Leopold ^c   Ugurel, Selma ^b   Hafner, Christian ^c   Pastrana, Diana V ^d   Buck, Christopher B ^d   Cerroni, Lorenzo ^a   Theiler, Anna ^a   Becker, Jürgen C ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; VEMURAFENIB; VIRUS DNA; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; AUSTRIA; BK VIRUS; CELL PROLIFERATION; CONTROLLED STUDY; DNA ISOLATION; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN POLYOMAVIRUS 10; HUMAN POLYOMAVIRUS 6; HUMAN POLYOMAVIRUS 7; HUMAN POLYOMAVIRUS 9; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MERKEL CELL POLYOMAVIRUS; MUTATIONAL ANALYSIS; NONHUMAN; POLYOMA VIRUS; RETROSPECTIVE STUDY; SKIN CARCINOMA; TRICHODYSPLASIA SPINULOSA ASSOCIATED POLYOMAVIRUS; TUMOR VIRUS; UNIVERSITY HOSPITAL; VIRUS DETECTION; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, SQUAMOUS CELL; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MELANOMA; MIDDLE AGED; MUTATION; ONCOGENE RAS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; POLYOMAVIRUS INFECTIONS; REAL TIME POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TUMOR VIRUS INFECTIONS; VIROLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; GENES, RAS; HUMANS; INDOLES; MELANOMA; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; TUMOR VIRUS INFECTIONS;

EID: 84910116286     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.1116     Document Type: Article

References (42)

1. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments formetastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007;33(8):665-680.
2. Schadendorf D, Hauschild A. Melanoma in 2013: melanoma-the run of success continues. Nat Rev Clin Oncol. 2014;11(2):75-76.
3. Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother. 2011;45(11):1399-1405.
4. Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs. 2013;73(12):1367-1376.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417 (6892):949-954.
6. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
7. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
8. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30(3):316-321.
9. Su F, Viros A, Milagre C, et al.RASmutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3):207-215.
10. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464(7287):431-435.
11. Carnahan J., Beltran P.J., Babij C, et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther. 2010;9(8):2399-2410.
12. Arnault J.P., Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS,TP53, and TGFBR1. Clin Cancer Res. 2012;18 (1):263-272.
13. Cubie H.A. Diseases associated with human papillomavirus infection. Virology. 2013;445(1-2): 21-34.
14. Falchook GS, Rady P, Hymes S, et al. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol. 2013;149(3):322-326.
15. SeamanWT, Andrews E, Couch M, et al. Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. Virol J. 2010;7:194.
16. Becker JC, Houben R,Ugurel S, TrefzerU, Pfohler C, SchramaD.MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol. 2009;129(1):248-250.
17. Guastafierro A, Feng H, Thant M, et al. Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice.J VirolMethods. 2013;187(1):6-14.
18. Georgieva IA, Mauerer A, Groesser L, et al. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis [published online ahead of print June 4, 2013]. Am J Dermatopathol.
19. Groesser L, Herschberger E, Ruetten A, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet. 2012;44(7):783-787.
20. Pastrana DV, Pumphrey KA, Cuburu N, Schowalter RM, Buck CB. Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid. Virology. 2010;405(1):20-25.
21. Espinosa E, Grob JJ, Dummer R, et al. Treatment algorithms in stage IV melanoma [published online ahead of print January 9, 2014]. Am J Ther.
22. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patientswith metastatic melanoma. Br J Dermatol. 2012;167(5):1153-1160.
23. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
24. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimmers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
25. Holderfield M, Lorenzana E,Weisburd B, et al. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res. 2014;74 (8):2238-2245.
26. Iannacone MR, Gheit T,Waterboer T, et al. Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 2012;21 (8):1303-1313.
27. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096-1100.
28. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe. 2010;7(6):509-515.
29. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 2010; 6(7):e1001024.
30. Scuda N, Hofmann J, Calvignac-Spencer S, et al. A novel human polyomavirus closely related to the African green monkey-derived lymphotropic polyomavirus. J Virol. 2011;85(9):4586-4590.
31. Buck CB, Phan GQ, Raiji MT, Murphy PM, McDermott DH, McBride AA. Complete genome sequence of a tenth human polyomavirus. J Virol. 2012;86(19):10887.
32. Korup S, Rietscher J, Calvignac-Spencer S, et al. Identification of a novel human polyomavirus in organs of the gastrointestinal tract. PLoS One. 2013; 8(3):e58021.
33. Houben R, Shuda M,WeinkamR, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol. 2010;84(14):7064-7072.
34. Kazem S, van der Meijden E, Feltkamp MC. The trichodysplasia spinulosa-associated polyomavirus: virological background and clinical implications. APMIS. 2013;121(8):770-782.
35. Schrama D, Buck CB, Houben R, Becker JC. No evidence for association of HPyV6 or HPyV7 with different skin cancers. J Invest Dermatol. 2012;132 (1):239-241.
36. van der Meijden E, Bialasiewicz S, Rockett RJ, Tozer SJ, Sloots TP, Feltkamp MC. Different serologic behavior of MCPyV, TSPyV, HPyV6, HPyV7 and HPyV9 polyomaviruses found on the skin. PLoS One. 2013;8(11):e81078.
37. Wieland U, Silling S, HellmichM, Potthoff A, Pfister H, Kreuter A. Human polyomaviruses 6, 7, 9, 10 and trichodysplasia spinulosa-associated polyomavirus in HIV-infected men. J Gen Virol. 2014;95(pt 4):928-932.
38. Antonsson A, Erfurt C, Hazard K, et al. Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J Gen Virol. 2003;84(pt 7): 1881-1886.
39. Wieland U, Mauch C, Kreuter A, Krieg T, Pfister H. Merkel cell polyomavirus DNA in persons without Merkel cell carcinoma. Emerg Infect Dis. 2009;15(9):1496-1498.
40. Moore PS, Chang Y. The conundrum of causality in tumor virology: the cases of KSHV and MCV [published online ahead of print December 1, 2013]. Semin Cancer Biol.
41. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol. 2011; 131(8):1745-1753.
42. Ganzenmueller T, Hage E, Yakushko Y, et al. No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients. Exp Dermatol. 2013;22(11):725-729.